The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
HOME > COMMENTARY
COMMENTARY
- Verify Acceptability of Prices before Revising Pricing Rule
November 30, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics （２）
November 2, 2009
- Pharmacology of Aging and Longevity: Looking for Anti-Aging Therapeutics （１）
November 2, 2009
- How Not to License a Drug into Japan
October 12, 2009
- TOPICS／Abbott Named One of the "Best Places to Launch a Career" by BusinessWeek
October 5, 2009
- NHI Drug Pricing System Reform Becomes Further Unpredictable Following Gov't Change
October 5, 2009
- COMMENTARY／Pharma Industry Watches New DPJ Administration with Both Anticipation and Concerns
September 21, 2009
- COMMENTARY／Will It Be Possible to Eliminate Use of Multiple Antipsychotics in Massive Doses?
September 14, 2009
- COMMENTARY／Establish Solid Criteria for Switching Ethical Drugs to OTC Status
September 14, 2009
- COMMENTARY／Korosho to Embark on Japanese Version of Sentinel Initiative
September 7, 2009
- COMMENTARY／Wholesalers Need to Analyze Causes of Their Failure
August 24, 2009
- COMMENTARY／Hisamitsu Aims at Growth by Fusing Its and Noven's Technologies
August 24, 2009
- COMMENTARY／Permitting MSs to Take MR Cert. Exam Offers New Business Opportunity to Wholesalers
August 3, 2009
- COMMENTARY／Fair Profits Are Essential to Spread Regenerative Medicine
August 3, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(1)
July 20, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(2)
July 20, 2009
- COMMENTARY／Global Pharmas Enhance Their Presence in Japan
July 13, 2009
- COMMENTARY／Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
- COMMENTARY／Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
- SURVEY／RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
ページ
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…